Moderna (MRNA) Q4 2025 earnings review
Cost Cuts Deliver, But Pipeline Stumbles
Moderna is successfully shrinking its cost base but struggling to diversify revenue. While the company aggressively slashed operating expenses by $2.2 billion in 2025, the growth narrative took a significant hit with a 'Refusal-to-File' letter from the FDA regarding its seasonal flu vaccine. Q4 revenue fell 30% YoY to $0.7 billion as COVID fatigue persists. Management guides for 'up to 10%' revenue growth in 2026, but with the flu vaccine delayed and Norovirus needing a second season of data, the path to profitability relies almost entirely on further austerity rather than near-term commercial breakouts.
🐂 Bull Case
Moderna delivered on its promise to right-size the business. Q4 R&D expenses dropped 31% YoY and SG&A fell 12%. FY26 guidance implies another ~20% cut in total operating expenses (to ~$4.0B from $5.0B in FY25).
The Merck collaboration (Intismeran) showed positive 5-year Phase 2b data with a 49% reduction in recurrence/death. Phase 3 melanoma data is expected in 2026, providing a massive potential catalyst unrelated to respiratory viruses.
🐻 Bear Case
Receiving a 'Refusal-to-File' letter from the FDA for the seasonal flu vaccine (mRNA-1010) is a major red flag, indicating the application was not even sufficient for review. This delays a key revenue diversification pillar.
Despite cost cuts, Moderna burned ~$1.4B in cash YoY (ending at $8.1B vs $9.5B), and that figure includes drawing $600M from a credit facility. Operations are still significantly loss-making ($(2.8)B Net Loss for FY25).
⚖️ Verdict: 🔴
Bearish. The aggressive cost-cutting is necessary and commendable, but the investment thesis depends on the pipeline replacing lost COVID revenues. The FDA Refusal-to-File on the flu vaccine and the Norovirus delay suggest significant execution risks in that transition.
Key Themes
FDA 'Refusal-to-File' Shock
Moderna received a Refusal-to-File letter from the U.S. FDA regarding its seasonal flu vaccine (mRNA-1010). This is rare for a major biotech and suggests fundamental deficiencies in the application, not just a request for more data. While filings were accepted in the EU and Canada, the U.S. market is critical for the 2026 revenue growth targets.
Operational Austerity Accelerating
The company reduced FY25 operating expenses to $5.0B, beating the original $5.0-$5.2B range. Q4 Cost of Sales plummeted 39% YoY, driven by lower inventory write-downs and manufacturing wind-down costs. 2026 guidance forecasts total OpEx of ~$4.0B ($3B R&D + $1B SG&A), a further $1B reduction that extends the cash runway.
COVID Revenue Cliff
Product sales fell 31% YoY in Q4 to $645M. FY25 revenue of $1.9B is down 40% from $3.2B in FY24. The business is shrinking faster than the cost base can be adjusted, leading to significant negative operating leverage.
Norovirus Timeline Drift
The Norovirus (mRNA-1403) Phase 3 trial is fully enrolled but requires a second season for case accrual. Data readout is now expected in 2026, pushing potential revenue generation further out. This adds pressure on the 2026 balance sheet as the company burns cash waiting for new product launches.
Oncology Pipeline maturing
Positive 5-year data for Intismeran (mRNA-4157) in melanoma showed a 49% risk reduction in recurrence or death vs Keytruda alone. With Phase 3 data expected in 2026 and trials fully enrolled in bladder and renal cancer, this remains the highest-upside asset in the portfolio.
Other KPIs
Stable/Managed. Down from $9.5B at YE24. However, this includes a $600M draw from a credit facility. Without the debt draw, cash burn would have been ~$2.0B for the year. Management guides to $5.5-$6.0B ending cash in 2026, implying continued burn of ~$2.1-$2.6B next year.
Improving. Loss narrowed from $(3.6)B in FY24. Q4 Net Loss was $(826)M vs $(1.1)B YoY. The improvement is driven entirely by cost cutting ($2.2B reduced OpEx) rather than revenue growth.
Improving significantly. Down 39% YoY. While inventory write-downs ($144M) persist, they are lower than prior periods, indicating better inventory management relative to the shrinking demand.
Guidance
Stable/Slight Acceleration. After a 40% decline in FY25, management sees a floor. Growth is predicated on 'mNEXSPIKE expansion' and international partnerships. This target is at risk if the Flu vaccine rejection prevents a 2026 launch in the US.
Decelerating. This represents a further ~20% cut from FY25's $5.0B OpEx. Management is effectively shrinking the company to match the post-pandemic reality.
Decreasing. Implies a cash burn of approximately $2.1B to $2.6B in FY26 (excluding further debt draws). This confirms the company will not be cash-flow positive in 2026.
Key Questions
Flu Vaccine Refusal-to-File Details
A Refusal-to-File is a severe regulatory setback. Was this due to manufacturing/CMC issues or clinical data deficiencies? Does this make a 2026 US launch impossible?
Norovirus Commercial Timing
With the need for a second season of data collection in 2026, is a commercial launch now pushed to 2027 or 2028? How does this impact the bridge to cash-flow breakeven?
Debt Strategy
You drew $600M on the credit facility this quarter. Given the guided cash burn for 2026, do you anticipate drawing the remaining capacity, and at what point does capital raising become a discussion?